Randomized Phase-II Trial Evaluating Induction Therapy With Idarubicin and Etoposide Plus Sequential or Concurrent Azacitidine and Maintenance Therapy With Azacitidine.
Phase of Trial: Phase II
Latest Information Update: 15 Nov 2016
At a glance
- Drugs Azacitidine (Primary) ; Azacitidine; Cytarabine; Etoposide; Idarubicin
- Indications Acute myeloid leukaemia
- Focus Therapeutic Use
- 10 Jun 2017 Biomarkers information updated
- 12 Nov 2016 Status changed from active, no longer recruiting to completed.
- 20 Oct 2016 This trial was completed in Germany (end date: 2016-10-02), according to European Clinical Trials Database.